MedTrace Logo

The Potential Cardioprotective Effect of Addition of Atorvastatin in Breast Cancer Patients

NCT07668076 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 44

Last updated 2026-06-25

No results posted yet for this study

Summary

the study aims to evaluate the cardioprotective effect of atorvastatin in breast cancer female patients treated with doxorubicin based chemotherapy

Conditions

Interventions

DRUG

Atorvastatin

atorvastatin 40 mg orally once daily for 3 months.

Sponsors & Collaborators

  • Damanhour University

    lead OTHER

Principal Investigators

  • Gamal Omran, phD · Faculty of pharmacy

  • Noha El-Bassiouny, phD · Faculty of pharmacy

  • Amira B Kassem, PhD · Faculty of pharmacy

  • Mohamed omar · Damanhour Oncology Center

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-11-15
Primary Completion
2024-10-20
Completion
2024-10-20

Countries

  • Egypt

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07668076 on ClinicalTrials.gov